Anthony R. Cox

Prof. Anthony R. Cox

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2021 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
DSDaranjit Sandhu
Daranjit Sandhu
AAAlbert A. Antolin
Albert A. Antolin
ACAnthony R. Cox
Anthony R. Cox
Alan JonesAlan Jones
Alan Jones
Aims: The aim of this study was to determine the differences and potential mechanistic rationale for observed adverse drug reactions (ADRs) between four approved PARP inhibitors (PARPi).Methods: The Medicines and Healthcare products Regulatory Authority (MHRA) Yellow Card drug analysis profiles and NHS secondary care medicines database enabled the identification of suspected ADRs associated with the PARPi in the UK from launch to 2020. The polypharmacology of the PARPi were data‐mined from several public data sources.Results: The overall ADRs per 100 000 Rx identified across the four PARPi are statistically significant (χ2 test, P < .001). Rucaparib has the greatest relative suspected ADRs, which can be explained by its least clean kinome and physicochemical properties. The suspected gastrointestinal ADRs of rucaparib and niraparib can be ascribed to their kinase polypharmacology. Suspected blood and lymphatic system ADRs of PARPi can be linked to their high volume of distribution (Vd). The thrombocytopenia rate of niraparib > rucaparib > olaparib tracked with the Vd trend.Hypertension is only associated with niraparib and could be explained by the therapeutically achievable inhibition of DYRK1A and/or transporters. Arrhythmia cases are potentially linked to the structural features of hERG ion‐channel inhibition found in rucaparib and niraparib. Enhanced psychiatric/nervous disorders associated with niraparib can be interpreted from the diverse neurotransporter off‐targets reported.Conclusions: Despite their similar mode of action, the differential polypharmacology of PARP inhibitors influences their ADR profile.

1 April 2011 in Drug Safety
Verified
Journal Article
Closed access
PDF file
TBTehreem F. Butt
Tehreem F. Butt
ACAnthony R. Cox
Anthony R. Cox
HLHelen Lewis
Helen Lewis
RFRobin E. Ferner
Robin E. Ferner

18 May 2011 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
SLS. Lorimer
S. Lorimer
ACAnthony R. Cox
Anthony R. Cox
NLN. J. Langford
N. J. Langford

14 August 2017 in Drug Safety
Verified
Journal Article
Closed access
PDF file
RFRobin E. Ferner
Robin E. Ferner
CECraig Easton
Craig Easton
ACAnthony R. Cox
Anthony R. Cox

12 September 2021 in Drug Safety
Verified
Journal Article
Closed access
PDF file
Wadia Saad AlruqaybWadia Saad Alruqayb
Wadia Saad Alruqayb
MPMalcolm J. Price
Malcolm J. Price
VPVibhu Paudyal
Vibhu Paudyal
ACAnthony R. Cox
Anthony R. Cox

1 February 2004 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Closed access
PDF file
ACAnthony R. Cox
Anthony R. Cox
JMJ. F. Marriott
J. F. Marriott
KWK. A. Wilson
K. A. Wilson
RFR. E. Ferner
R. E. Ferner
Objectives: To assess the extent of teaching about the Committee on Safety of Medicine's Yellow Card scheme and adverse drug reactions within UK Schools of Medicine and Pharmacy. Methods: A self‐completed questionnaire sent to all heads of undergraduate schools of medicine and pharmacy within the UK. Results: The majority of undergraduate syllabuses feature the Yellow Card Scheme. Knowledge of the Yellow Card Scheme was assessed in 79% of pharmacy programmes and 57% of medical schools. Specialist speakers on the Yellow Card Scheme were infrequently used. Fewer than half of respondents provided students with a guide to reporting ADRs (43% pharmacy and 43% medical). There is some disagreement about the value of supplying students with printed material about the Yellow Card Scheme. Half of medical Schools did not think that supplying ‘Current Problems In Pharmacovigilance’ would be useful. Conclusions: It was found that in both medicine and pharmacy, courses differed substantially in teaching about the Yellow Card Scheme and adverse drug reactions (ADRs). There is scope for increased involvement of the Medicines and Healthcare products Regulatory Agency in undergraduate education, in line with recommendations from the National Audit Office.